Overview
The primary audience for these recommendations includes health professionals who are responsible for developing national and local health care guidelines and protocols (particularly those related to postpartum haemorrhage (PPH) prevention and treatment) and those involved in the provision of care to women and their newborns during labour and childbirth, including midwives, nurses, general medical practitioners and obstetricians, as well as managers of maternal and child health programmes, and relevant staff in ministries of health and training institutions, in all settings.
Web annexes (GRADE Evidence to Decision frameworks and Summary of Findings tables)
- Web annex 1: Oxytocin versus placebo or no treatment
- Web annex 2: Carbetocin versus placebo or no treatment
- Web annex 3: Misoprostol versus placebo or no treatment
- Web annex 4: Ergometrine/methylergometrine versus placebo or no treatment
- Web annex 5: Oxytocin and ergometrine versus placebo or no treatment
- Web annex 6: Injectable prostaglandins versus placebo or no treatment
- Web annex 7: Choice of uterotonic agents